Hospital
The Mary Lanning Memorial Hospital Association
The Mary Lanning Memorial Hospital Association was paid $12.82M by Medicaid between Jan 2018 and Dec 2024, across 223 billing codes. Its largest line is 99284, emergency room visit (serious) — 15% of everything it billed.
33Billing provider infoTHE MARY LANNING MEMORIAL HOSPITAL ASSOCIATION
HASTINGS, NE 68901
HASTINGS, NE 68901
33aNPI1831203488assigned 08/19/2006
33bProvider typeRural Acute Care Hospital
28Total paid$12.82M
24GClaims358,826
24DCodes billed223
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 49,650 | $1.78M | |
| 2019 | 47,574 | $1.90M | |
| 2020 | 35,336 | $1.18M | |
| 2021 | 83,164 | $2.66M | |
| 2022 | 90,863 | $3.05M | |
| 2023 | 39,524 | $1.57M | |
| 2024incomplete | 12,715 | $692K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 13,123 | 11,764 | $1.98M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.8% | 8,263 | 7,629 | $1.13M |
| 96361 | Intravenous infusion, hydration; each additional hour | 7.1% | 3,000 | 2,566 | $912K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.5% | 12,855 | 2,788 | $833K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 5.0% | 10,591 | 2,350 | $642K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 5.0% | 9,500 | 1,860 | $641K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.9% | 4,204 | 2,579 | $631K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.7% | 1,726 | 1,592 | $601K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.9% | 1,871 | 1,705 | $506K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.6% | 4,003 | 3,813 | $458K |
| G0378 | Hospital observation service, per hour | 2.9% | 1,498 | 1,310 | $371K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.2% | 4,800 | 3,589 | $277K |
211 more codes
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.8% | 1,572 | $226K |
| 99285 | Emergency room visit (most serious) | 1.7% | 1,636 | $215K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.5% | 490 | $191K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.2% | 972 | $152K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.1% | 1,733 | $136K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,694 | $127K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,946 | $113K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 767 | $110K |
| 80053 | Comprehensive metabolic panel | <1% | 22,123 | $109K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 926 | $106K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 608 | $106K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 325 | $106K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,452 | $92K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,485 | $87K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,675 | $74K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,980 | $73K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,154 | $64K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,005 | $64K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,978 | $63K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,697 | $59K |
| 87631 | <1% | 355 | $53K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 314 | $53K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,098 | $53K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 325 | $51K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,028 | $50K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,699 | $50K |
| 93971 | <1% | 352 | $49K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,593 | $44K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,439 | $44K |
| J3490 | Unclassified drugs | <1% | 15,708 | $42K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,472 | $42K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 141 | $39K |
| 80081 | <1% | 464 | $37K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 138 | $35K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,884 | $33K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,621 | $31K |
| 84702 | <1% | 4,304 | $27K | |
| 97161 | <1% | 978 | $26K | |
| 74018 | <1% | 494 | $25K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,574 | $25K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 951 | $25K |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,358 | $25K |
| 81001 | <1% | 8,485 | $24K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,242 | $24K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 106 | $23K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,745 | $22K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 468 | $22K |
| 88142 | <1% | 948 | $22K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 257 | $22K |
| 80061 | Lipid panel | <1% | 2,013 | $20K |
| 82805 | <1% | 295 | $18K | |
| 84439 | <1% | 1,741 | $18K | |
| 73630 | <1% | 451 | $17K | |
| 71250 | <1% | 182 | $16K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 240 | $16K |
| 73562 | <1% | 384 | $15K | |
| 87070 | <1% | 1,839 | $14K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,584 | $13K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 822 | $13K |
| 73610 | <1% | 264 | $13K | |
| 87077 | <1% | 2,307 | $12K | |
| 97165 | <1% | 256 | $12K | |
| 86140 | <1% | 4,142 | $12K | |
| 92526 | <1% | 1,399 | $12K | |
| Q3014 | Telehealth originating site facility fee | <1% | 891 | $12K |
| 87186 | <1% | 2,048 | $12K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 14 | $11K |
| 83735 | <1% | 4,179 | $11K | |
| 83880 | <1% | 1,046 | $10K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 67 | $10K |
| 97116 | <1% | 418 | $10K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,507 | $10K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 16,842 | $9K |
| 80050 | General health panel | <1% | 853 | $9K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 32 | $9K |
| 0099U | <1% | 59 | $9K | |
| 93017 | <1% | 30 | $8K | |
| 87507 | <1% | 26 | $8K | |
| 83690 | <1% | 3,665 | $8K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 13 | $8K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 8,914 | $7K |
| 84484 | <1% | 3,227 | $7K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,676 | $6K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,205 | $6K |
| 93970 | <1% | 42 | $6K | |
| A9270 | Non-covered item or service | <1% | 777 | $6K |
| 83605 | <1% | 2,074 | $5K | |
| 0097U | <1% | 40 | $5K | |
| 96367 | <1% | 131 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,224 | $5K |
| 85027 | <1% | 1,220 | $5K | |
| 82607 | <1% | 382 | $4K | |
| 85610 | <1% | 2,691 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 63 | $4K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 12 | $4K |
| 84145 | <1% | 801 | $4K | |
| A4217 | Sterile water/saline, 500 ml | <1% | 942 | $4K |
| 85651 | <1% | 988 | $4K | |
| 73110 | <1% | 45 | $4K | |
| 82962 | <1% | 2,219 | $3K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 158 | $3K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 16 | $3K |
| 82728 | <1% | 422 | $3K | |
| 87210 | <1% | 562 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,996 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,166 | $3K |
| 73030 | <1% | 100 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,683 | $3K |
| 97166 | <1% | 77 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 170 | $3K |
| 85730 | <1% | 1,063 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 103 | $2K |
| 88342 | <1% | 233 | $2K | |
| 86900 | <1% | 246 | $2K | |
| 80320 | <1% | 800 | $2K | |
| 76536 | <1% | 12 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 548 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 567 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,122 | $2K |
| 87486 | <1% | 39 | $2K | |
| 87581 | <1% | 39 | $2K | |
| 83550 | <1% | 366 | $1K | |
| 82570 | <1% | 355 | $1K | |
| 83540 | <1% | 408 | $1K | |
| 84153 | <1% | 116 | $1K | |
| 87040 | <1% | 443 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,594 | $1K |
| 97597 | <1% | 66 | $1K | |
| 94060 | <1% | 12 | $852.77 | |
| 77066 | Tomosynthesis, mammo | <1% | 13 | $789.21 |
| 93226 | <1% | 15 | $786.47 | |
| 73130 | <1% | 94 | $750.23 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 30 | $743.13 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 342 | $710.20 |
| 87075 | <1% | 84 | $678.02 | |
| 97162 | <1% | 116 | $646.80 | |
| 85378 | <1% | 812 | $642.69 | |
| 82951 | <1% | 40 | $600.64 | |
| 72110 | <1% | 15 | $551.09 | |
| 84146 | <1% | 58 | $536.50 | |
| 82043 | <1% | 139 | $478.90 | |
| 86850 | <1% | 47 | $448.55 | |
| 87205 | <1% | 129 | $431.73 | |
| 93225 | <1% | 15 | $416.91 | |
| 86901 | <1% | 246 | $411.63 | |
| 82565 | <1% | 219 | $393.14 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,073 | $351.69 |
| 82550 | <1% | 270 | $345.46 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 12 | $318.55 |
| 84156 | <1% | 157 | $306.17 | |
| 84100 | <1% | 131 | $259.68 | |
| 86762 | <1% | 15 | $248.78 | |
| 86780 | <1% | 17 | $228.76 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 1,521 | $210.65 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,895 | $193.31 |
| 87340 | <1% | 18 | $178.50 | |
| 86803 | <1% | 15 | $157.80 | |
| 82952 | <1% | 28 | $150.45 | |
| A6204 | Composite dressing, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | <1% | 952 | $131.25 |
| 81025 | <1% | 15 | $129.99 | |
| 85014 | <1% | 35 | $108.32 | |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 806 | $97.98 |
| 80178 | <1% | 14 | $81.60 | |
| 82746 | <1% | 14 | $71.64 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 136 | $69.84 |
| 80069 | <1% | 18 | $64.32 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 13 | $62.91 |
| 85018 | <1% | 35 | $54.16 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,546 | $46.57 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 385 | $45.66 |
| 80143 | <1% | 257 | $36.71 | |
| 80179 | <1% | 262 | $27.68 | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 160 | $25.71 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 119 | $13.44 |
| A4213 | Syringe, sterile, 20 cc or greater, each | <1% | 48 | $5.95 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 42 | $3.48 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 483 | $2.99 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 172 | $0.03 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 145 | $0.02 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 753 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 15 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 19 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 101 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 52 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 36 | $0.00 |
| 80329 | 0% | 49 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 69 | $0.00 |
| 82077 | 0% | 39 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 43 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 248 | $0.00 |
| A6223 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 16 sq. in., but less than or equal to 48 sq. in., without adhesive border, each dressing | 0% | 16 | $0.00 |
| 96376 | 0% | 12 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 13 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 18 | $0.00 |
| 80051 | 0% | 13 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 252 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 219 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 43 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 106 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 15 | $0.00 |
| A6258 | Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | 0% | 171 | $0.00 |
| A4210 | Needle-free injection device, each | 0% | 78 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 60 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 30 | $0.00 |
| 82310 | 0% | 13 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 12 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 15 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 31 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 76 | $0.00 |
| J7070 | Infusion, d5w, 1000 cc | 0% | 16 | $0.00 |
| 82947 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBARBER, ERIC (CEO)
| Provider | Location | Paid |
|---|---|---|
| The Mary Lanning Memorial Hospital Association | Hastings, NE | $4.32M |
| The Mary Lanning Memorial Hospital Association | Hastings, NE | $3.14M |
| The Mary Lanning Memorial Hospital Association | Hastings, NE | $346K |
| The Mary Lanning Memorial Hospital Association | Hastings, NE | $144K |
| The Mary Lanning Memorial Hospital Association | Hastings, NE | $117K |
| The Mary Lanning Memorial Hospital Association | Hastings, NE | $84K |
| The Mary Lanning Memorial Hospital Association | Hastings, NE | $66K |
| The Mary Lanning Memorial Hospital Association | Hastings, NE | $45K |
| The Mary Lanning Memorial Hospital Association | Blue Hill, NE | $29K |
| The Mary Lanning Memorial Hospital Association | Hastings, NE | $731.01 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.